Date:
April 18, 2022
Issue #:
1648
Summary:
The FDA has approved Seglentis (Esteve/Kowa), an
oral combination of tramadol hydrochloride, a weak
opioid agonist and weak serotonin and norepinephrine
reuptake inhibitor (SNRI), and celecoxib, a COX-2
selective nonsteroidal anti-inflammatory drug
(NSAID), for use in adults with acute pain that is
severe enough to require an opioid and for which
alternative treatment options are inadequate.
oral combination of tramadol hydrochloride, a weak
opioid agonist and weak serotonin and norepinephrine
reuptake inhibitor (SNRI), and celecoxib, a COX-2
selective nonsteroidal anti-inflammatory drug
(NSAID), for use in adults with acute pain that is
severe enough to require an opioid and for which
alternative treatment options are inadequate.